Search results
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 96% as Wall Street Analysts Expect?
Zacks via Yahoo Finance· 2 years agoThe mean of analysts' price targets for Karyopharm Therapeutics (KPTI) points to a 96.1% upside in...
Great week for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) institutional investors after losing 84%...
Simply Wall St. via Yahoo Finance· 6 months agoKey Insights Given the large stake in the stock by institutions, Karyopharm Therapeutics' stock...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is favoured by institutional owners who hold 74% of the...
Simply Wall St. via Yahoo Finance· 12 months agoKey Insights Significantly high institutional ownership implies Karyopharm Therapeutics' stock price...
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoKaryopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 1.59% and 9.08%,...
Karyopharm Therapeutics (NASDAQ:KPTI) adds US$104m to market cap in the past 7 days, though...
Simply Wall St. via Yahoo Finance· 4 months agoIt is a pleasure to report that the Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is up 139% in the...
There's No Escaping Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Muted Revenues Despite A 27% Share...
Simply Wall St. via Yahoo Finance· 1 year agoKaryopharm Therapeutics Inc. (NASDAQ:KPTI) shares have continued their recent momentum with a 27%...
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement
Benzinga via Yahoo Finance· 2 years agoBiogen Inc. (NASDAQ: BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ: KPTI) that it has opted...
Karyopharm Therapeutics (NASDAQ:KPTI) shareholders have endured a 87% loss from investing in the...
Simply Wall St. via Yahoo Finance· 1 year agoIt's not possible to invest over long periods without making some bad investments. But really bad...
Will Karyopharm Therapeutics (KPTI) Report Negative Q1 Earnings? What You Should Know
Zacks via Yahoo Finance· 1 year agoKaryopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for...
Karyopharm Therapeutics Inc (KPTI) Reports Q3 2023 Earnings, Total Revenue of $36.0 Million
GuruFocus.com via Yahoo Finance· 7 months agoThird Quarter 2023 total revenue of $36.0 million, with U.S. XPOVIO net product revenue of $30.2...